Shire increases ADHD focus with UCB drugs acquisition
This article was originally published in Scrip
Executive Summary
Shire is to pay €55 million up front for the rights to UCB's attention deficit hyperactivity disorder (ADHD) treatments Equasym IR and XL (methylphenidate hydrochloride) outside the US, Canada and Barbados.